Filing Details
- Accession Number:
- 0001209191-19-037895
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-06-18 21:43:40
- Reporting Period:
- 2019-06-14
- Accepted Time:
- 2019-06-18 21:43:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1717452 | Odonate Therapeutics Inc. | ODT | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1178579 | C Kevin Tang | 4747 Executive Drive Suite 510 San Diego CA 92121 | Chief Executive Officer | Yes | Yes | Yes | No |
| 1191935 | Tang Capital Partners Lp | 4747 Executive Drive Suite 510 San Diego CA 92121 | No | No | Yes | No | |
| 1232621 | Tang Capital Management Llc | 4747 Executive Drive Suite 510 San Diego CA 92121 | No | No | Yes | No | |
| 1495904 | G John Lemkey | 4747 Executive Drive Suite 510 San Diego CA 92121 | Chief Operating Officer | No | Yes | No | No |
| 1759910 | S Michael Hearne | 4747 Executive Drive Suite 510 San Diego CA 92121 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-06-14 | 18,608 | $24.95 | 13,274,646 | No | 4 | P | Indirect | By LP |
| Common Stock | Acquisiton | 2019-06-17 | 1,905 | $26.20 | 13,276,551 | No | 4 | P | Indirect | By LP |
| Common Stock | Acquisiton | 2019-06-17 | 8,137 | $26.95 | 13,284,688 | No | 4 | P | Indirect | By LP |
| Common Stock | Acquisiton | 2019-06-18 | 21,350 | $26.89 | 13,306,038 | No | 4 | P | Indirect | By LP |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | By LP |
| No | 4 | P | Indirect | By LP |
| No | 4 | P | Indirect | By LP |
| No | 4 | P | Indirect | By LP |
Footnotes
- The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $24.44 to $25.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 5 herein.
- The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management,LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares ofcommon stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authorityto vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
- The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $25.89 to $26.82.
- The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $26.90 to $27.00.
- The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $26.58 to $27.00.
Billionaire Hedge Funds
